Home Tags Mirvetuximab soravtansine

Tag: Mirvetuximab soravtansine

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize...

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in 1993, have entered into an...

AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize...

Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...

ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...

Confirmatory Study of Mirvetuximab Soravtansine in Ovarian Cancer on Track to...

In a statement earlier today, ImmunoGen confirmed that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity

Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin®; Genentech/Roche)...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer...

The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known as IMGN853, compared to chemotherapy...

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...

ImmunoGen and FDA Discuss Ongoing Development for Mirvetuximab Soravtansine

The United States Food and Drug Administration (FDA) has recommended that ImmunoGen conducts a new Phase III randomized trial to evaluate the safety and...

FORWARD I Phase III Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian...

The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Amid Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes...

A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company's...